HK scientists find probiotic mix's benefits in liver cancer treatment

By RJ Whitehead

- Last updated on GMT

Dr Hani El-Nezami, Dr Gianni Panagiotou and  Dr Li Jun
Dr Hani El-Nezami, Dr Gianni Panagiotou and Dr Li Jun

Related tags: Cancer

Hong Kong researchers have developed a novel probiotic mixture that may have potential therapeutic effects on liver cancer.

The team, led by Hani El-Nezami and Gianni Panagiotou of the School of biological Sciences at the University of Hong Kong, formulated Prohep, which when tested on mice was found to significantly slow down the growth of hepatocellular carcinoma (HCC) and reduce the size and weight of tumours.

An aggressive tumour and second most deadly cancer type globally, hepatocellular carcinoma accounts for most liver cancers and carries a sobering prognosis. At around US$6,000 per month, the cost of its treatment using targeted therapy is high. 

Probiotics, however, which are commonly found in dairy food products, cost a fraction of this amount, meaning that microbiome-based therapeutics could therefore offer a cheaper approach in HCC intervention.

fig
1. Control group: fed with normal diet after tumour injection; 2. Cisplatin group: fed with chemotherapy drug Cisplatin after tumour injection; 3. ProPre group: fed with Prohep one week before the tumour injection. Other treatments the same as ProTreat group; 4.ProTreat group: fed with normal diet and Prohep after tumour injection

The researchers found that they could reduce tumour weight and size by 40% after feeding mice with Prohep one week before a tumour was injected. 

The findings were published in the Proceedings of the National Academy of Sciences of the United States of America​.

While the beneficial role of probiotics in lowering gastrointestinal inflammation and preventing colorectal cancer has been frequently demonstrated, their immunomodulatory effects and mechanism in suppressing the growth of extra-intestinal tumours had not been explored until the HKU team began their study.

They found that the Prohep probiotic mixture’s beneficial effect was closely related to the abundance of certain beneficial bacteria that produce anti-inflammatory metabolites, which subsequently regulated the pro-inflammatory immune cell population via the crosstalk between gut and tumour. 

Modulated gut microbiota, when applied to the liver, then suppressed hepatocellular carcinoma growth in the mice.

The researchers believe that Prohep has the potential to offer solutions for future treatment, or the development of alternative or complementary therapeutic and prophylactic methods for hepatocellular carcinoma.

Dr El-Nezami said: “The successful demonstration of probiotic efficacy in retarding hepatocellular carcinoma tumour growth in a pre-clinical model will warrant further testing of our approach in a microbiome-based intervention trial in cancer patients​. 

The combined data from these studies could be applied to product development of immunotherapeutic drugs containing the studied bacterial communities. This will offer an opportunity for local pharmaceutical industries to adventure into this area of research to develop novel drugs, based on microbial ecosystems, to reduce HCC risks​.”

He said that research was now needed on how to consume the probiotic mixture to obtain the best results, and to develop more efficient bacterial cocktails.

Over the last few years, there have been a lot of studies that associate different disease types, such as infection diseases, cancer and metabolic diseases, with disturbances in the gut microbiota. However, in most of these cases the statistical analysis will propose just a couple of bacteria as the main contributors on the disease progression​.”

For complex diseases, he said, bacterial communities of 20, 30 or 50 different species would be necessary for inducing the biological processes that will positively influence the host. 

Therefore the research team’s follow-up studies on HCC progression and the interplay with the gut microbiota are in that direction, to develop more efficient bacterial cocktails. Moreover, there are many more parameters that need to be elucidated in relation to this study​.” 

Whether these bacterial cocktails will be used as the basis for a drug or in tandem depends on the stage, size and grade of the tumour, and should ultimately be tested on humans, he added.

Related news

Related products

show more

HRB probiotics: The gift of life for infant health

HRB probiotics: The gift of life for infant health

Morinaga Milk Industry Co., Ltd. | 29-Jun-2020 | Technical / White Paper

Bifidobacteria are among the first colonizers of human gut, and certain species are recognised as Human-Residential Bifidobacteria (HRB) - the natural...

Related suppliers

Follow us

Products

View more

Webinars